1U5 Stock Overview
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Wave Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.45 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$4.04 |
| Beta | -0.92 |
| 1 Month Change | 12.14% |
| 3 Month Change | -47.09% |
| 1 Year Change | -5.22% |
| 3 Year Change | 363.04% |
| 5 Year Change | -43.52% |
| Change since IPO | -84.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1U5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.9% | -1.7% | 1.7% |
| 1Y | -5.2% | -25.8% | 16.5% |
Return vs Industry: 1U5 exceeded the German Pharmaceuticals industry which returned -25.3% over the past year.
Return vs Market: 1U5 underperformed the German Market which returned 16% over the past year.
Price Volatility
| 1U5 volatility | |
|---|---|
| 1U5 Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 1U5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1U5's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 288 | Paul B. Bolno | wavelifesciences.com |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).
Wave Life Sciences Ltd. Fundamentals Summary
| 1U5 fundamental statistics | |
|---|---|
| Market cap | €890.10m |
| Earnings (TTM) | -€99.19m |
| Revenue (TTM) | €92.66m |
Is 1U5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1U5 income statement (TTM) | |
|---|---|
| Revenue | US$104.94m |
| Cost of Revenue | US$166.86m |
| Gross Profit | -US$61.92m |
| Other Expenses | US$50.41m |
| Earnings | -US$112.33m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | -59.00% |
| Net Profit Margin | -107.04% |
| Debt/Equity Ratio | 0% |
How did 1U5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 08:55 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wave Life Sciences Ltd. is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Steven Seedhouse | CGS International |